Nanobiotix (NBTX)
(Delayed Data from NSDQ)
$6.10 USD
+0.05 (0.83%)
Updated May 3, 2024 04:00 PM ET
After-Market: $6.26 +0.16 (2.62%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Income Statements
Fiscal Year end for Nanobiotix SA Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 39 | 5 | 3 | 3 | 3 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 39 | 5 | 3 | 3 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 68 | 54 | 65 | 44 | 55 |
Income After Depreciation & Amortization | -29 | -49 | -62 | -42 | -52 |
Non-Operating Income | 2 | 4 | 8 | 0 | 1 |
Interest Expense | 16 | 15 | 1 | -3 | 6 |
Pretax Income | -43 | -60 | -56 | -38 | -57 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -43 | -60 | -56 | -38 | -57 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -43 | -60 | -56 | -38 | -57 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -27 | -48 | -60 | -40 | -50 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 2 | 2 | 2 |
Income After Depreciation & Amortization | -29 | -49 | -62 | -42 | -52 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 36.76 | 34.78 | 34.82 | 23.99 | 21.63 |
Diluted EPS Before Non-Recurring Items | -1.17 | -1.76 | -1.60 | -1.60 | -2.63 |
Diluted Net EPS (GAAP) | -1.17 | -1.73 | -1.60 | -1.58 | -2.63 |
Fiscal Year end for Nanobiotix SA Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |